


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of the claims and listing of the claims in the application:

1. (Original) A method for treating a subject for glaucoma, comprising:
administering a therapeutically effective amount of a deprenyl compound to a subject such that the subject is treated for glaucoma.
2. (Original) The method of claim 1, wherein the deprenyl compound is represented by the structure:



in which

R₁ is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxy carbonyl, or aryloxy carbonyl;

R₂ is hydrogen or alkyl;

R₃ is a single bond, alkylene, or $-(\text{CH}_2)_n-\text{X}-(\text{CH}_2)_m-$;

in which X is O, S, or N-methyl; m is 1 or 2; and n is 0, 1, or 2;

R₄ is alkyl, alkenyl, alkynyl, heterocyclyl, aryl or aralkyl; and

R₅ is alkylene, alkenylene, alkynylene and alkoxylenylene; and

R₆ is C₃-C₆ cycloalkyl or



R₂ and R₄-R₃ are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group;


and pharmaceutically acceptable salts thereof.

3. (Original) The method of claim 2, wherein R₁ is a group that can be removed *in vivo*.

4. (Original) The method of claim 2, wherein R_1 is hydrogen.
5. (Original) The method of claim 2, wherein R_1 is alkyl.
6. (Original) The method of claim 5, wherein R_1 is methyl.
7. (Original) The method of claim 2, wherein R_2 is methyl.
8. (Original) The method of claim 2, wherein R_3 is methylene.
9. (Original) The method of claim 2, wherein R_4 is aryl.
10. (Original) The method of claim 2, wherein R_4 is phenyl.
11. (Original) The method of claim 2, wherein R_5 is methylene.
12. (Original) The method of claim 2, wherein R_6 is




13. (Original) The method of claim 2, wherein the deprenyl compound has the structure



wherein R_1 is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, or aryloxycarbonyl.

14. (Original) The method of claim 2, wherein the deprenyl compound is represented by the structure:



in which

R₁ is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, or aryloxycarbonyl;

R₂ is hydrogen or alkyl;


R₃ is a bond or methylene; and

R₄ is aryl or aralkyl; or

R₂ and R₄-R₃ are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group;

and pharmaceutically acceptable salts thereof.

15. (Original) The method of claim 2, wherein the deprenyl compound is represented by the structure:



in which

R₂ is hydrogen or alkyl;


R₃ is a bond or methylene; and

R₄ is aryl or aralkyl; or

R₂ and R₄-R₃ are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group; and

R₅ is alkylene, alkenylene, alkynylene and alkoxylenes;

16. (Currently Amended) The method of claim 2, wherein the deprenyl compound is represented by the structure:



in which

R₁ is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, or aryloxycarbonyl;

A is a substituent independently selected for each ~~occurrence~~ occurrence from the group consisting of halogen, hydroxyl, alkyl, alkoxyl, cyano, nitro, amino, carboxyl, -CF₃, or azido;

n is 0 or an integer from 1 to 5;

and pharmaceutically acceptable salts thereof.

17. (Original) The method of claim 1, wherein the deprenyl compound is (-)-deprenyl.
18. (Original) The method of claim 1, wherein the deprenyl compound is (-)-pargyline.
19. (Original) The method of claim 1, wherein the deprenyl compound is (-)-desmethyldeprenyl.
20. (Cancelled)